The data is: People with the disease
A new study published Monday in the journal Nature found that among cases involving the variant, called B.1.1.7, patients had a 55% higher chance of death within four weeks after their advanced test.
The study’s authors surveyed around 2.2 million people who tested positive in England between September and mid-February, and then compared the number of deaths among those with B.1.1.7 to those infected with other strains. After controlling for variables including patients’ age, gender, race, and lifestyle, the researchers found that with the original virus, about six out of every 1,000 people in Scotland could be expected to die. their 60s which is positive. But this number rises to around nine out of 1,000 with B.1.1.7.
“Despite major advances in COVID-19 treatment, we have seen more deaths in 2021 than we did over the first eight months of pandemic in 2020. Our work is helping to ‘explain why, “Nick Davies, lead author of the study and epidemiologist at the London School of Hygiene & Tropical Medicine, said in a press release.
In January and February, 42,000 people in England died of COVID-19.
Sanas
Climbing evidence indicates that the B.1.1.7 variant is more lethal
B.1.1.7 was detected outside London in September, but initial evidence showed that snoring was no more lethal. Then in January, UK Prime Minister Boris Johnson announced that the odds related to death appeared to be higher.
Research published last week confirmed in that journal BMJ. He found B.1.1.7 to be more lethal than other series – and even more deadly than the results of a Nature study suggest. BMJ researchers studied nearly 55,000 pairs of people in the UK. Within each pair, one had tested positive for B.1.1.7 and the other had tested positive for difference.
The study found that the B.1.1.7 variant was 64% more lethal than the other variants within the four weeks after a positive test.
Johnson’s news in January was based on research compiled by the New and Emerging Respiratory Virus Risk Advisory Group, which found that people with B.1.1.7 in the UK had a 30% higher mortality rate than those with the original virus.
A follow-up analysis from Public Health England analyzed data collected between late November and early January, and found that B.1.1.7 was 65% more lethal than other strains. Meanwhile, researchers from the University of Exeter looked at samples collected between October and the end of January and found that people with the variant were almost twice as likely to die.
Higher mortality may be associated with higher viral loads
Increased strain mortality may be frozen up to B.1.1.7 infected loads with viral loads on average, resulting in increased viral loads when infected . Higher viral loads, several studies show, are associated with a higher risk of death and worsening infection.
“That was the first thing that definitely came to my mind,” William Schaffner, an infectious disease specialist at Vanderbilt University, told Insider previously. “It would make really good sense.”
It is also possible that increased movement of the strain just gives the virus a better chance of getting more people at greater risk of serious illness. More portable snoring means that people are more likely to become infected if they are exposed; B.1.1.7 is between 50% and 70% more infectious than the original version of the virus. This higher transmission could be due to several mutations in the genetic code for the virus’s spike protein, which it uses to attack cells. These tweaks may make it easier for the B.1.1.7 variant to spread.
“Getting to more vulnerable people who are older or upside down may just be a matter of more infectious virus
But it is another possibility that the greater movement of change has indirectly contributed to a higher mortality rate as a result of the pressure it has placed on the UK healthcare system. The number of COVID-19 cases per day soared in the four months since B.1.1.7 was detected, jumping from 3,899 new cases on September 20 to more than 68,000 cases on January 8.
The spike in cases has put pressure on UK hospitals and healthcare facilities, which may have hurt patient outcomes.
“If your affairs get out of control, your deaths will get out of control as your health system comes under pressure,” Mike Ryan, executive director of the World Health Organisation’s health emergency program, said in January.
Current vaccines work against B.1.1.7
B.1.1.7 was found in 94 countries, including the USA.
But in recent studies, both Pfizer and Moderna found that their views stood out against the opposite. Other vaccines, including those from Johnsen & Johnsen and AstraZeneca, also protect people from B.1.1.7.
But these views do not appear to be as effective overall against the variance first found in South Africa, B.1.351, and the pressure found in Brazil, referred to as P.1 .
This is likely because these two variables share a mutation that prevents the antibodies created in response to the original virus from being identified. This genetic tweak is mostly missing in B.1.1.7, although UK researchers found 11 cases of B.1.1.7 with that shift in a set of more than 200,000 samples.
Studies have not found that B.1.351 or P.1 are more lethal than the original virus.